Skip to main content
SpringerLink
Log in

Pharmacogenetics of the Efficacy of Antipsychotic Drugs in Schizophrenia

  • Chapter
  • First Online:
Genetic Influences on Response to Drug Treatment for Major Psychiatric Disorders

Abstract

Response to pharmacotherapy is highly variable, complex and difficult to predict. Genetic factors influence, at least partially, clinical response to drugs. It has been proposed that the use of genetic information may help to predict patient’s response to medications. In the last decades, pharmacogenetic studies have produced numerous reports of genetic associations with treatment efficacy and related side effects. However, only a limited number of these findings may have clinical utility in psychiatry. In this chapter, we will review pharmacogenetic findings in relation to common antipsychotic drugs used for the treatment of schizophrenia and discuss their clinical applicability.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Aberg K, Adkins DE, Bukszar J, Webb BT, Caroff SN, Miller DD, Sebat J, Stroup S, Fanous AH, Vladimirov VI, Mcclay JL, Lieberman JA, Sullivan PF, Van Den Oord EJ (2010) Genomewide association study of movement-related adverse antipsychotic effects. Biol Psychiatry 67:279–282

    Article  PubMed Central  PubMed  Google Scholar 

  2. Adkins DE, Aberg K, Mcclay JL, Bukszar J, Zhao Z, Jia P, Stroup TS, Perkins D, Mcevoy JP, Lieberman JA, Sullivan PF, Van Den Oord EJ (2011) Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol Psychiatry 16:321–332

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Al Hadithy AF, Ivanova SA, Pechlivanoglou P, Semke A, Fedorenko O, Kornetova E, Ryadovaya L, Brouwers JR, Wilffert B, Bruggeman R, Loonen AJ (2009) Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia. Prog Neuropsychopharmacol Biol Psychiatry 33:475–481

    Article  CAS  PubMed  Google Scholar 

  4. Al-janabi I, Arranz MJ, Blakemore AI, Saiz PA, Susce MT, Glaser PE, Clark D, De Leon J (2009) Association study of serotonergic gene variants with antipsychotic-induced adverse reactions. Psychiatr Genet 19:305–311

    Article  PubMed  Google Scholar 

  5. Alkelai A, Greenbaum L, Rigbi A, Kanyas K, Lerer B (2009) Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. Psychopharmacology (Berl) 206:491–499

    Article  CAS  Google Scholar 

  6. Altar CA, Hornberger J, Shewade A, Cruz V, Garrison J, Mrazek D (2013) Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy. Int Rev Psychiatry 25:509–533

    Article  PubMed  Google Scholar 

  7. Anttila S, Illi A, Kampman O, Mattila KM, Lehtimäki T, Leinonen E (2004) Interaction between NOTCH4 and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics. Pharmacogenetics 14:303–307

    Article  CAS  PubMed  Google Scholar 

  8. Arranz MJ, De Leon J (2007) Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 12:707–747

    Article  CAS  PubMed  Google Scholar 

  9. Arranz MJ, Kapur S (2008) Pharmacogenetics in psychiatry: are we ready for widespread clinical use? Schizophr Bull 34:1130–1144

    Article  PubMed Central  PubMed  Google Scholar 

  10. Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M, Lesch KP, Meyer JF, Sham P, Collier DA, Murray RM, Kerwin RW (2000) Pharmacogenetic prediction of clozapine response. Lancet 355:1615–1616

    Article  CAS  PubMed  Google Scholar 

  11. Arranz MJ, Munro J, Osborne S, Collier D, Kerwin RW (2000) Difficulties in replication of results. Lancet 356:1359–1360

    Article  CAS  PubMed  Google Scholar 

  12. Arranz MJ, Munro J, Sham P, Kirov G, Murray RM, Collier DA, Kerwin RW (1998) Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res 32:93–99

    Article  CAS  PubMed  Google Scholar 

  13. Arranz MJ, Munro JC (2011) Toward understanding genetic risk for differential antipsychotic response in individuals with schizophrenia. Expert Rev Clin Pharmacol 4:389–405

    Article  PubMed  Google Scholar 

  14. Arranz MJ, Rivera M, Munro JC (2011) Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs 25:933–969

    Article  CAS  PubMed  Google Scholar 

  15. Athanasiou MC, Dettling M, Cascorbi I, Mosyagin I, Salisbury BA, Pierz KA, Zou W, Whalen H, Malhotra AK, Lencz T, Gerson SL, Kane JM, Reed CR (2011) Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J Clin Psychiatry 72:458–463

    Article  CAS  PubMed  Google Scholar 

  16. Bertolino A, Caforio G, Blasi G, Rampino A, Nardini M, Weinberger DR, Dallapiccola B, Sinibaldi L, Douzgou S (2007) COMT Val158Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia. Schizophr Res 95:253–255

    Article  PubMed  Google Scholar 

  17. Bilic P, Jukic V, Vilibic M, Savic A, Bozina N (2014) Treatment-resistant schizophrenia and DAT and SERT polymorphisms. Gene 543:125–132

    Article  CAS  PubMed  Google Scholar 

  18. Bondolfi G, Morel F, Crettol S, Rachid F, Baumann P, Eap CB (2005) Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther Drug Monit 27:539–543

    Article  CAS  PubMed  Google Scholar 

  19. Bozina N, Kuzman MR, Medved V, Jovanovic N, Sertic J, Hotujac L (2008) Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. J Psychiatr Res 42:89–97

    Article  PubMed  Google Scholar 

  20. Bozina N, Medved V, Kuzman MR, Sain I, Sertic J (2007) Association study of olanzapine-induced weight gain and therapeutic response with SERT gene polymorphisms in female schizophrenic patients. J Psychopharmacol 21:728–734

    Article  CAS  PubMed  Google Scholar 

  21. Brandl EJ, Frydrychowicz C, Tiwari AK, Lett TA, Kitzrow W, Büttner S, Ehrlich S, Meltzer HY, Lieberman JA, Kennedy JL, Müller DJ, Puls I (2012) Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain. Prog Neuropsychopharmacol Biol Psychiatry 38:134–141

    Article  CAS  PubMed  Google Scholar 

  22. Brandl EJ, Kennedy JL, Muller DJ (2014) Pharmacogenetics of antipsychotics. Can J Psychiatry 59:76–88

    PubMed Central  PubMed  Google Scholar 

  23. Brockmöller J, Kirchheiner J, Schmider J, Walter S, Sachse C, Müller-oerlinghausen B, Roots I (2002) The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 72:438–452

    Article  PubMed  Google Scholar 

  24. Cabaleiro T, López-rodríguez R, Román M, Ochoa D, Novalbos J, Borobia A, Carcas A, Abad-santos F (2015) Pharmacogenetics of quetiapine in healthy volunteers: association with pharmacokinetics, pharmacodynamics, and adverse effects. Int Clin Psychopharmacol 30:82–88

    Article  PubMed  Google Scholar 

  25. Chagnon YC, Merette C, Bouchard RH, Emond C, Roy MA, Maziade M (2004) A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses. Mol Psychiatry 9:1067–1074

    Article  CAS  PubMed  Google Scholar 

  26. Chowdhury NI, Tiwari AK, Souza RP, Zai CC, Shaikh SA, Chen S, Liu F, Lieberman JA, Meltzer HY, Malhotra AK, Kennedy JL, Müller DJ (2013) Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene. Pharmacogenomics J 13:272–279

    Article  CAS  PubMed  Google Scholar 

  27. Czerwensky F, Leucht S, Steimer W (2013) MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain? Int J Neuropsychopharmacol 16:2103–2109

    Article  CAS  PubMed  Google Scholar 

  28. De Leon J, Correa JC, Ruaño G, Windemuth A, Arranz MJ, Diaz FJ (2008) Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels. Schizophr Res 98:40–46

    Article  PubMed  Google Scholar 

  29. De Leon J, Susce MT, Pan RM, Koch WH, Wedlund PJ (2005) Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J Clin Psychopharmacol 25:448–456

    Article  PubMed  Google Scholar 

  30. De Vos A, Van Der Weide J, Loovers HM (2011) Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. Pharmacogenomics J 11:359–367

    Article  PubMed  Google Scholar 

  31. Drago A, Giegling I, Schafer M, Hartmann AM, Konte B, Friedl M, Serretti A, Rujescu D (2014) Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment. Pharmacogenet Genomics 24:314–319

    Article  CAS  PubMed  Google Scholar 

  32. Du J, Zhang A, Wang L, Xuan J, Yu L, Che R, Li X, Gu N, Lin Z, Feng G, Xing Q, He L (2010) Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients. J Psychopharmacol 24:1115–1120

    Article  CAS  PubMed  Google Scholar 

  33. Eap CB, Bender S, Jaquenoud Sirot E, Cucchia G, Jonzier-Perey M, Baumann P, Allorge D, Broly F (2004) Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol 24:214–219

    Article  CAS  PubMed  Google Scholar 

  34. Ellingrod VL, Miller D, Schultz SK, Wehring H, Arndt S (2002) CYP2D6 polymorphisms and atypical antipsychotic weight gain. Psychiatr Genet 12:55–58

    Article  PubMed  Google Scholar 

  35. Ferrari M, Bolla E, Bortolaso P, Callegari C, Poloni N, Lecchini S, Vender S, Marino F, Cosentino M (2012) Association between CYP1A2 polymorphisms and clozapine-induced adverse reactions in patients with schizophrenia. Psychiatry Res 200:1014–1017

    Article  CAS  PubMed  Google Scholar 

  36. Fijal BA, Kohler J, Ostbye K, Ahl J, Houston JP (2013) Association of candidate gene polymorphisms with diastolic blood pressure change in patients treated with duloxetine. Psychiatry Res 206:313–314

    Article  CAS  PubMed  Google Scholar 

  37. Fleeman N, Martin Saborido C, Payne K, Boland A, Dickson R, Dundar Y, Fernández santander A, Howell S, Newman W, Oyee J, Walley T (2011) The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review. Health Technol Assess 15:1–102

    Google Scholar 

  38. Fleeman N, Mcleod C, Bagust A, Beale S, Boland A, Dundar Y, Jorgensen A, Payne K, Pirmohamed M, Pushpakom S, Walley T, De Warren-Penny P, Dickson R (2010) The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation. Health Technol Assess 14:1–157, iii

    CAS  PubMed  Google Scholar 

  39. Gareeva AE, Zakirov DF, Valinurov RG, Khusnutdinova EK (2013) Polymorphism of RGS2 gene: genetic markers of risk for schizophrenia and pharmacogenetic markers of typical neuroleptics efficiency. Mol Biol (Mosk) 47:934–941

    Article  CAS  Google Scholar 

  40. Greenbaum L, Alkelai A, Zozulinsky P, Kohn Y, Lerer B (2012) Support for association of HSPG2 with tardive dyskinesia in Caucasian populations. Pharmacogenomics J 12:513–520

    Article  CAS  PubMed  Google Scholar 

  41. Gregoor JG, Van Der Weide J, Loovers HM, VAN Megen HJ, Egberts TC, Heerdink ER (2011) Polymorphisms of the LEP, LEPR and HTR2C gene: obesity and BMI change in patients using antipsychotic medication in a naturalistic setting. Pharmacogenomics 12:919–923

    Article  CAS  PubMed  Google Scholar 

  42. Gregoor JG, Van Der Weide J, Mulder H, Cohen D, Van Megen HJ, Egberts AC, Heerdink ER (2009) Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication. J Clin Psychopharmacol 29:21–25

    Article  CAS  PubMed  Google Scholar 

  43. Hall-Flavin DK, Winner JG, Allen JD, Jordan JJ, Nesheim RS, Snyder KA, Drews MS, Eisterhold LL, Biernacka JM, Mrazek DA (2012) Using a pharmacogenomic algorithm to guide the treatment of depression. Transl Psychiatry 2, e172

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  44. Harrison PJ (2015) Recent genetic findings in schizophrenia and their therapeutic relevance. J Psychopharmacol 29:85–96

    Article  PubMed Central  PubMed  Google Scholar 

  45. Ikeda M, Tomita Y, Mouri A, Koga M, Okochi T, Yoshimura R, Yamanouchi Y, Kinoshita Y, Hashimoto R, Williams HJ, Takeda M, Nakamura J, Nabeshima T, Owen MJ, O’donovan MC, Honda H, Arinami T, Ozaki N, Iwata N (2010) Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case–control association approaches. Biol Psychiatry 67:263–269

    Article  CAS  PubMed  Google Scholar 

  46. Inada T, Koga M, Ishiguro H, Horiuchi Y, Syu A, Yoshio T, Takahashi N, Ozaki N, Arinami T (2008) Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia. Pharmacogenet Genomics 18:317–323

    Article  CAS  PubMed  Google Scholar 

  47. Ingelman-Sundberg M (2004) Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 25:193–200

    Article  CAS  PubMed  Google Scholar 

  48. Joober R, Benkelfat C, Lal S, Bloom D, Labelle A, Lalonde P, Turecki G, Rozen R, Rouleau GA (2000) Association between the methylenetetrahydrofolate reductase 677C-->T missense mutation and schizophrenia. Mol Psychiatry 5:323–326

    Article  CAS  PubMed  Google Scholar 

  49. Kastelic M, Koprivsek J, Plesnicar BK, Serretti A, Mandelli L, Locatelli I, Grabnar I, Dolzan V (2010) MDR1 gene polymorphisms and response to acute risperidone treatment. Prog Neuropsychopharmacol Biol Psychiatry 34:387–392

    Article  CAS  PubMed  Google Scholar 

  50. Kingbäck M, Karlsson L, Zackrisson AL, Carlsson B, Josefsson M, Bengtsson F, Ahlner J, Kugelberg FC (2012) Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood. Forensic Sci Int 214:124–134

    Article  PubMed  Google Scholar 

  51. Kirchheiner J, Meineke I, Müller G, Bauer S, Rohde W, Meisel C, Roots I, Brockmöller J (2004) Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. Clin Pharmacokinet 43:267–278

    Article  CAS  PubMed  Google Scholar 

  52. Knol W, Van Marum RJ, Jansen PA, Strengman E, Al Hadithy AF, Wilffert B, Schobben AA, Ophoff RA, Egberts TC (2013) Genetic variation and the risk of haloperidol-related parkinsonism in elderly patients: a candidate gene approach. J Clin Psychopharmacol 33:405–410

    Article  CAS  PubMed  Google Scholar 

  53. Kohlrausch FB, Salatino-Oliveira A, Gama CS, Lobato MI, Belmonte-De-Abreu P, Hutz MH (2010) Influence of serotonin transporter gene polymorphisms on clozapine response in Brazilian schizophrenics. J Psychiatr Res 44:1158–1162

    Article  PubMed  Google Scholar 

  54. Kohlrausch FB, Severino-Gama C, Lobato MI, Belmonte-De-Abreu P, Carracedo A, Hutz MH (2013) The CYP1A2 -163C > A polymorphism is associated with clozapine-induced generalized tonic-clonic seizures in Brazilian schizophrenia patients. Psychiatry Res 209:242–245

    Article  CAS  PubMed  Google Scholar 

  55. Koning JP, Vehof J, Burger H, Wilffert B, Al Hadithy A, Alizadeh B, Van Harten PN, Snieder H, Genetic Risk and Outcome in Psychosis (GROUP) investigators (2012) Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients. Psychopharmacology (Berl) 219:727–736

    Article  CAS  Google Scholar 

  56. Krebs MO, Guillin O, Bourdell MC, Schwartz JC, Olie JP, Poirier MF, Sokoloff P (2000) Brain derived neurotrophic factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia. Mol Psychiatry 5:558–562

    Article  CAS  PubMed  Google Scholar 

  57. Lane HY, Lin CC, Huang CH, Chang YC, Hsu SK, Chang WH (2004) Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders. Schizophr Res 67:63–70

    Article  PubMed  Google Scholar 

  58. Lane HY, Liu YC, Huang CL, Chang YC, Wu PL, Huang CH, Tsai GE (2008) RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia. J Clin Psychopharmacol 28:64–68

    Article  CAS  PubMed  Google Scholar 

  59. Lane HY, Liu YC, Huang CL, Chang YC, Wu PL, Lu CT, Chang WH (2006) Risperidone-related weight gain: genetic and nongenetic predictors. J Clin Psychopharmacol 26:128–134

    Article  CAS  PubMed  Google Scholar 

  60. Lavedan C, Licamele L, Volpi S, Hamilton J, Heaton C, Mack K, Lannan R, Thompson A, Wolfgang CD, Polymeropoulos MH (2009) Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol Psychiatry 14:804–819

    Article  CAS  PubMed  Google Scholar 

  61. Lawford BR, Barnes M, Swagell CD, Connor JP, Burton SC, Heslop K, Voisey J, Morris CP, Nyst P, Noble EP, Young RM (2013) DRD2/ANKK1 Taq1A (rs 1800497 C > T) genotypes are associated with susceptibility to second generation antipsychotic-induced akathisia. J Psychopharmacol 27:343–348

    Article  CAS  PubMed  Google Scholar 

  62. Lee ST, Ryu S, Kim SR, Kim MJ, Kim S, Kim JW, Lee SY, Hong KS (2012) Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response. J Clin Psychopharmacol 32:441–448

    Article  CAS  PubMed  Google Scholar 

  63. Leon J, Susce MT, Pan RM, Wedlund PJ, Orrego ML, Diaz FJ (2007) A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry 40:93–102

    Article  PubMed  Google Scholar 

  64. Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R, Aschauer HN, Mccreadie RG, Ohlraun S, Ferrier N, Masellis M, Verga M, Scharfetter J, Rietschel M, Lovlie R, Levy UH, Meltzer HY, Kennedy JL, Steen VM, Macciardi F (2002) Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 27:105–119

    Article  CAS  PubMed  Google Scholar 

  65. Lieberman JA, Stroup TS, Mcevoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223

    Article  CAS  PubMed  Google Scholar 

  66. Liu YR, Loh EW, Lan TH, Chen SF, Yu YH, Chang YH, Huang CJ, Hu TM, Lin KM, Yao YT, Chiu HJ (2010) ADRA1A gene is associated with BMI in chronic schizophrenia patients exposed to antipsychotics. Pharmacogenomics J 10:30–39

    Article  CAS  PubMed  Google Scholar 

  67. Malhotra AK, Correll CU, Chowdhury NI, Müller DJ, Gregersen PK, Lee AT, Tiwari AK, Kane JM, Fleischhacker WW, Kahn RS, Ophoff RA, Meltzer HY, Lencz T, Kennedy JL (2012) Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry 69:904–912

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  68. Mancama D, Arranz MJ, Munro J, Osborne S, Makoff A, Collier D, Kerwin R (2002) Investigation of promoter variants of the histamine 1 and 2 receptors in schizophrenia and clozapine response. Neurosci Lett 333:207–211

    Article  CAS  PubMed  Google Scholar 

  69. Mcclay JL, Adkins DE, Aberg K, Bukszar J, Khachane AN, Keefe RS, Perkins DO, Mcevoy JP, Stroup TS, Vann RE, Beardsley PM, Lieberman JA, Sullivan PF, Van Den Oord EJ (2011) Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology 36:616–626

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  70. Mcclay JL, Adkins DE, Aberg K, Stroup S, Perkins DO, Vladimirov VI, Lieberman JA, Sullivan PF, Van Den Oord EJ (2011) Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol Psychiatry 16:76–85

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  71. Molero P, Ortuño F, Zalacain M, Patiño-García A (2007) Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment. Pharmacogenomics J 7:418–426

    Article  CAS  PubMed  Google Scholar 

  72. Müller DJ, Zai CC, Sicard M, Remington E, Souza RP, Tiwari AK, Hwang R, Likhodi O, Shaikh S, Freeman N, Arenovich T, Heinz A, Meltzer HY, Lieberman JA, Kennedy JL (2012) Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. Pharmacogenomics J 12:156–164

    Article  PubMed  Google Scholar 

  73. Nikisch G, baumann P, Oneda B, Kiessling B, Weisser H, Mathé AA, Yoshitake T, Kehr J, Wiedemann G, Eap CB (2011) Cytochrome P450 and ABCB1 genetics: association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study. J Psychopharmacol 25:896–907

    Article  CAS  PubMed  Google Scholar 

  74. Ota VK, Spíndola LN, Gadelha A, Dos Santos Filho AF, Santoro ML, Christofolini DM, Bellucco FT, Ribeiro-Dos-Santos Â, Santos S, Mari JEJ, Melaragno MI, Bressan RA, Smith MEA, Belangero SI (2012) DRD1 rs4532 polymorphism: a potential pharmacogenomic marker for treatment response to antipsychotic drugs. Schizophr Res 142:206–208

    Article  PubMed  Google Scholar 

  75. Park YM, Chung YC, Lee SH, Lee KJ, Kim H, Byun YC, Lim SW, Paik JW, Lee HJ (2006) Weight gain associated with the alpha2a-adrenergic receptor −1,291 C/G polymorphism and olanzapine treatment. Am J Med Genet B Neuropsychiatr Genet 141B:394–397

    Article  CAS  PubMed  Google Scholar 

  76. Rajkumar AP, Poonkuzhali B, Kuruvilla A, Srivastava A, Jacob M, Jacob KS (2012) Outcome definitions and clinical predictors influence pharmacogenetic associations between HTR3A gene polymorphisms and response to clozapine in patients with schizophrenia. Psychopharmacology (Berl) 224:441–449

    Article  CAS  Google Scholar 

  77. Rau T, Wohlleben G, Wuttke H, Thuerauf N, Lunkenheimer J, Lanczik M, Eschenhagen T (2004) CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Clin Pharmacol Ther 75:386–393

    Article  CAS  PubMed  Google Scholar 

  78. Saiz PA, Susce MT, Clark DA, Kerwin RW, Molero P, Arranz MJ, De Leon J (2008) An investigation of the alpha1A-adrenergic receptor gene and antipsychotic-induced side-effects. Hum Psychopharmacol 23:107–114

    Article  CAS  PubMed  Google Scholar 

  79. Schroth W, Hamann U, Fasching PA, Dauser S, Winter S, Eichelbaum M, Schwab M, Brauch H (2010) CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin Cancer Res 16:4468–4477

    Article  CAS  PubMed  Google Scholar 

  80. Sickert L, Müller DJ, Tiwari AK, Shaikh S, Zai C, DE Souza R, De Luca V, Meltzer HY, Lieberman JA, Kennedy JL (2009) Association of the alpha 2A adrenergic receptor -1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans. Pharmacogenomics 10:1169–1176

    Article  CAS  PubMed  Google Scholar 

  81. Suzuki T, Mihara K, Nakamura A, Nagai G, Kagawa S, Nemoto K, Ohta I, Arakaki H, Uno T, Kondo T (2011) Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther Drug Monit 33:21–24

    Article  CAS  PubMed  Google Scholar 

  82. Suzuki Y, Fukui N, Tsuneyama N, Watanabe J, Ono S, Sugai T, Saito M, Inoue Y, Someya T (2012) Effect of the cytochrome P450 2D6*10 allele on risperidone metabolism in Japanese psychiatric patients. Hum Psychopharmacol 27:43–46

    Article  CAS  PubMed  Google Scholar 

  83. Tsai MH, Lin KM, Hsiao MC, Shen WW, Lu ML, Tang HS, Fang CK, Wu CS, Lu SC, Liu SC, Chen CY, Liu YL (2010) Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics 11:537–546

    Article  CAS  PubMed  Google Scholar 

  84. van der Weide J, van Baalen-Benedek EH, Kootstra-Ros JE (2005) Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype. Ther Drug Monit 27:478–483

    Article  PubMed  Google Scholar 

  85. Wang J, Mei H, Chen W, Jiang Y, Sun W, Li F, Fu Q, Jiang F (2012) Study of eight GWAS-identified common variants for association with obesity-related indices in Chinese children at puberty. Int J Obes (Lond) 36:542–547

    Article  Google Scholar 

  86. Wang L, Yu L, He G, Zhang J, Zhang AP, Du J, Tang RQ, Zhao XZ, Ma J, Xuan JK, Xiao Y, Gu NF, Feng GY, Xu MQ, Xing QH, He L (2007) Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients. Neurosci Lett 414:1–4

    Article  CAS  PubMed  Google Scholar 

  87. Wei Z, Wang L, Yu T, Wang Y, Sun L, Wang T, Huo R, Li Y, Wu X, Qin S, Xu Y, Feng G, He L, Xing Q (2013) Histamine H4 receptor polymorphism: a potential predictor of risperidone efficacy. J Clin Psychopharmacol 33:221–225

    Article  CAS  PubMed  Google Scholar 

  88. Wei Z, Wang L, Zhang M, Xuan J, Wang Y, Liu B, Shao L, Li J, Zeng Z, Li T, Liu J, Wang T, Qin S, Xu Y, Feng G, He L, Xing Q (2012) A pharmacogenetic study of risperidone on histamine H3 receptor gene (HRH3) in Chinese Han schizophrenia patients. J Psychopharmacol 26:813–818

    Article  PubMed  Google Scholar 

  89. Weickert TW, Goldberg TE, Mishara A, Apud JA, Kolachana BS, Egan MF, Weinberger DR (2004) Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol Psychiatry 56:677–682

    Article  CAS  PubMed  Google Scholar 

  90. Wu R, Zhao J, Shao P, Ou J, Chang M (2011) Genetic predictors of antipsychotic-induced weight gain: a case-matched multi-gene study. Zhong Nan Da Xue Xue Bao Yi Xue Ban 36:720–723

    CAS  PubMed  Google Scholar 

  91. Xiang Q, Zhao X, Zhou Y, Duan JL, Cui YM (2010) Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety. J Clin Pharmacol 50:659–666

    Article  CAS  PubMed  Google Scholar 

  92. Xing Q, Gao R, Li H, Feng G, Xu M, Duan S, Meng J, Zhang A, Qin S, He L (2006) Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics 7:987–993

    Article  CAS  PubMed  Google Scholar 

  93. Yasui-Furukori N, Saito M, Nakagami T, Kaneda A, Tateishi T, Kaneko S (2006) Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 30:286–291

    Article  CAS  PubMed  Google Scholar 

  94. Zai GC, Zai CC, Chowdhury NI, Tiwari AK, Souza RP, Lieberman JA, Meltzer HY, Potkin SG, Müller DJ, Kennedy JL (2012) The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain. Prog Neuropsychopharmacol Biol Psychiatry 39:96–101

    Article  CAS  PubMed  Google Scholar 

  95. Zhang JP, Lencz T, Geisler S, Derosse P, Bromet EJ, Malhotra AK (2013) Genetic variation in BDNF is associated with antipsychotic treatment resistance in patients with schizophrenia. Schizophr Res 146:285–288

    Article  PubMed Central  PubMed  Google Scholar 

  96. Zhang XR, Zhang ZJ, Zhu RX, Yuan YG, Jenkins TA, Reynolds GP (2011) Sexual dysfunction in male schizophrenia: influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes. Pharmacogenomics 12:1127–1136

    Article  CAS  PubMed  Google Scholar 

  97. Zhao QZ, Liu BC, Zhang J, Wang L, Li XW, Wang Y, Ji J, Yang FP, Wan CL, Xu YF, Feng GY, He L, He G (2012) Association between a COMT polymorphism and clinical response to risperidone treatment: a pharmacogenetic study. Psychiatr Genet 22:298–299

    Article  CAS  PubMed  Google Scholar 

  98. Zivković M, Mihaljević-Peles A, Bozina N, Sagud M, Nikolac-Perkovic M, Vuksan-Cusa B, Muck-Seler D (2013) The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol. J Clin Psychopharmacol 33:593–599

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fundació Docència i Recerca Mútua Terrassa, c/Sant Antoni, 19, Terrassa, 08221, Spain

    María J. Arranz PhD

  2. Department of Psychiatry – CIBERSAM, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

    María J. Arranz PhD & Josefina Perez Blanco MD

  3. Department of Anthropology, University of Barcelona, Barcelona, Spain

    Barbara Arias Samperiz

Authors
  1. María J. Arranz PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Josefina Perez Blanco MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Barbara Arias Samperiz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to María J. Arranz PhD .

Editor information

Editors and Affiliations

  1. Department of Adult Psychiatry, Poznan University of Medical Scienc, Poznan, Poland

    Janusz K. Rybakowski

  2. Department of Biomedical and Neuromotor, University of Bologna, Bologna, Italy

    Alessandro Serretti

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Arranz, M.J., Blanco, J.P., Samperiz, B.A. (2016). Pharmacogenetics of the Efficacy of Antipsychotic Drugs in Schizophrenia. In: Rybakowski, J., Serretti, A. (eds) Genetic Influences on Response to Drug Treatment for Major Psychiatric Disorders. Adis, Cham. https://doi.org/10.1007/978-3-319-27040-1_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-27040-1_1

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-27038-8

  • Online ISBN: 978-3-319-27040-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation